18F-FDG and 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model

Journal of Nuclear Medicine

Volumn 50, Issue 7, 2009, Pages 1102-1109

  Brepoels, Lieselot ^a,b   Stroobants, Sigrid ^a,b   Verhoef, Gregor ^a   De Groot, Tjibbe ^a,b   Mortelmans, Luc ^a,b   De Wolf Peeters, Christiane ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU Leuven   (Belgium)

Author keywords

18F FDG; 18F FLT; Lymphoma; PET; Therapy response

Indexed keywords

3' FLUOROTHYMIDINE F 18; CYCLIN D1; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TEMSIROLIMUS; TORISOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; DRUG UPTAKE; ENZYME INHIBITION; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LEUKEMIA CELL; MALE; MANTLE CELL LYMPHOMA; MONITORING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DIDEOXYNUCLEOSIDES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; METABOLIC CLEARANCE RATE; MICE; MICE, SCID; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RADIOPHARMACEUTICALS; SIROLIMUS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 67650081272     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.062208     Document Type: Article

References (28)

1. Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464-4471.
2. Brepoels L, Stroobants S, De Wolf-Peeters C, Verhoef G. Prospective evaluation on the value of FDG-PET/CT for response assessment in DLBCL after 1 week of R-CHOP [abstract]. Ann Oncol. 2008;19(suppl 4):204P.
3. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
4. 18FFDG uptake in tumor lesions after chemotherapy. J Nucl Med. 2007;48:390-399.
5. 18F]FLT: portrait of a proliferation marker. Eur J Nucl Med Mol Imaging. 2002;29:165-169.
6. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926-1945.
7. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev. 2007;33:78-84.
8. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202-4210.
9. 18F-FDG PET. J Nucl Med. 2004;45:226-231.
10. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720-724.
11. 18FLT PET. Eur J Nucl Med Mol Imaging. 2004;31:928.
12. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
13. Buck AK, Bommer M, Stilgenbauer S. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055-11061.
14. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659-1672.
15. 18F-FLT can differentiate tumor from granuloma in experimental rat models [abstract]. J Nucl Med. 2006;47(suppl 1):177P.
16. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.
17. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging. 2005;32:525-533.
18. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66:5549-5554.
19. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1996;58:373-395.
20. Haberkorn U, Altmann A, Kamencic H, et al. Glucose transport and apoptosis after gene therapy with HSV thymidine kinase. Eur J Nucl Med. 2001;28:1690-1696.
21. Perumal M, Pillai RG, Barthel H, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006;66:8558-8564.
22. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.
23. 18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res. 2007;67:11463-11469.
24. 18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775-1782.
25. 3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590-4597.
26. 18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412-419.
27. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
28. 18F]FDG uptake correlate with the viable tumor cell fraction? Eur J Nucl Med Mol Imaging. 2003;30:682-688.